Neurocrine Biosciences | NBIX - Gross Profit On Sales


Neurocrine Biosciences reported $787.9M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Acadia Pharmaceuticals USD 257.76M 778K Dec/2025
Agios Pharmaceuticals USD 18.09M 6.89M Dec/2025
ALKERMES USD 338.34M 72.51M Dec/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Amgen USD 6.48B 307M Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Cytokinetics USD 17.76M 15.82M Dec/2025
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Exelixis USD 572.18M 7M Dec/2025
Gilead Sciences USD 6.31B 106M Dec/2025
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Incyte USD 1.39B 118.68M Dec/2025
Ionis Pharmaceuticals USD 195M 40M Dec/2025
Nektar Therapeutics USD 13.75M 650K Jun/2024
Neurocrine Biosciences USD 787.9M 7M Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
Prothena USD 2.42M 38.52M Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Repligen USD 103.83M 3.32M Dec/2025
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
Teva Pharmaceutical Industries USD 2.66B 351M Dec/2025
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025
Xoma 992K 846K Jun/2024